PE

Peptron, Inc.

Develops sustained-release peptide medicines for chronic & neurodegenerative disorders.

087010 | KO

Overview

Corporate Details

ISIN(s):
KR7087010005
LEI:
Country:
South Korea
Address:
대전광역시 유성구 유성대로1628번길 37-24, 대전광역시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Peptron, Inc., established in 1997, is a biotechnology company specializing in the development of peptide-based medicines. The company's core focus is its proprietary sustained-release (SR) drug delivery platform technology, known as SmartDepot, which enables the formulation of long-acting medications that can extend a drug's release profile from weekly to monthly intervals. Peptron's development pipeline targets treatments for various chronic, life-threatening, and neurodegenerative disorders. The company is actively developing exenatide as a drug for neurodegenerative conditions, supported by an exclusive license for related NIH patents.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-29 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 101.1 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.1 MB
2025-08-05 00:00
Transaction in Own Shares
자기주식처분결과보고서
Korean 17.8 KB
2025-08-05 00:00
Share Issue/Capital Change
증권발행결과(자율공시)
Korean 6.2 KB
2025-07-28 00:00
Capital/Financing Update
주요사항보고서(교환사채권발행결정)
Korean 42.6 KB
2025-07-28 00:00
Transaction in Own Shares
주요사항보고서(자기주식처분결정)
Korean 37.0 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.1 MB
2025-04-18 00:00
Legal Proceedings Report
투자판단관련주요경영사항(임상시험계획자진취하등) (PND3174의 제1a상 임상시험계획 자진취하)
Korean 10.6 KB
2025-03-31 00:00
Post-Annual General Meeting Information
[기재정정]정기주주총회결과
Korean 29.4 KB
2025-03-28 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 26.0 KB
2025-03-28 00:00
Board/Management Information
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Korean 10.4 KB
2025-03-28 00:00
Board/Management Information
[기재정정]사외이사의선임ㆍ해임또는중도퇴임에관한신고
Korean 13.2 KB
2025-03-20 00:00
Audit Report / Information
감사보고서제출
Korean 17.7 KB
2025-03-20 00:00
Audit Report / Information
사업보고서 (2024.12)
Korean 473.5 KB
2025-03-19 00:00
Pre-Annual General Meeting Information
[기재정정]주주총회소집결의
Korean 18.6 KB

Automate Your Workflow. Get a real-time feed of all Peptron, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Peptron, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Peptron, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Tourmaline Bio, Inc. Logo
Develops an anti-IL-6 antibody for cardiovascular, inflammatory, and immune diseases.
United States of America
TRML
TOWA PHARMACEUTICAL CO.,LTD. Logo
Manufactures and markets high-quality, accessible generic drugs for various therapeutic areas.
Japan
4553
Transcode Therapeutics, Inc. Logo
Develops targeted RNA therapies for metastatic cancer using a proprietary nanoparticle delivery platform.
United States of America
RNAZ
Travere Therapeutics, Inc. Logo
Develops therapies for rare kidney and metabolic diseases, with an FDA-approved treatment for IgA nephropathy.
United States of America
TVTX
Traws Pharma, Inc. Logo
Develops oral small-molecule therapies for respiratory viral diseases and cancer.
United States of America
TRAW
TScan Therapeutics, Inc. Logo
Developing TCR-engineered T-cell therapies for solid and hematologic cancers.
United States of America
TCRX
TSUMURA & CO. Logo
A leader in Japanese Kampo herbal medicine, producing prescription and OTC formulations.
Japan
4540
TuHURA Biosciences, Inc./NV Logo
Phase 3 immuno-oncology firm developing therapeutics to overcome cancer therapy resistance.
United States of America
HURA
TURK İLAÇ VE SERUM SANAYİ A.Ş. Logo
Turkish producer of pharmaceuticals, specializing in IV solutions and vaccines for hospitals.
Türkiye
TRILC
Tvardi Therapeutics, Inc. Logo
Developing oral STAT3 inhibitors to treat cancers and fibrosis-driven diseases.
United States of America
TVRD

Talk to a Data Expert

Have a question? We'll get back to you promptly.